Difference between revisions of "Non-small cell lung cancer, HER2-mutated"
Jump to navigation
Jump to search
(Created page with "{{#lst:Section editor transclusions|nsclc}} Note: these are regimens tested in biomarker-specific populations, please see the '''main NSCLC page...") |
Warner-admin (talk | contribs) m (Text replacement - "{| class="wikitable" style="float:right; margin-left: 5px;" |- |back to top |}" to "") |
||
Line 9: | Line 9: | ||
=Metastatic disease, all lines of therapy= | =Metastatic disease, all lines of therapy= | ||
==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ==Trastuzumab deruxtecan monotherapy {{#subobject:7hg71v|Regimen=1}}== | ||
− | + | ||
− | |||
− | |||
− | |||
===Regimen {{#subobject:f3eig9|Variant=1}}=== | ===Regimen {{#subobject:f3eig9|Variant=1}}=== | ||
{| class="wikitable" style="width: 60%; text-align:center;" | {| class="wikitable" style="width: 60%; text-align:center;" |
Revision as of 11:05, 26 July 2022
Section editor transclusions Note: these are regimens tested in biomarker-specific populations, please see the main NSCLC page for other regimens.
3 regimens on this page
4 variants on this page
|
Metastatic disease, all lines of therapy
Trastuzumab deruxtecan monotherapy
Regimen
Study | Years of enrollment | Evidence |
---|---|---|
Li et al. 2021 (DESTINY-Lung01) | 2018-2020 | Phase 2 |
Biomarker eligibility criteria
- HER2 mutations
Antibody-drug conjugate therapy
- Trastuzumab deruxtecan (Enhertu) 6.4 mg/kg IV once on day 1
21-day cycles
References
- DESTINY-Lung01: Li BT, Smit EF, Goto Y, Nakagawa K, Udagawa H, Mazières J, Nagasaka M, Bazhenova L, Saltos AN, Felip E, Pacheco JM, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Acharyya S, Vitazka P, Shahidi J, Planchard D, Jänne PA; DESTINY-Lung01 Trial Investigators. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer. N Engl J Med. 2021 Sep 18. Epub ahead of print. link to original article contains verified protocol PubMed NCT03505710